Trial Profile
Randomized olmesartan and diabetes microalbuminuria prevention study (ROADMAP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies; Hypertension in diabetes; Proteinuria
- Focus Registrational; Therapeutic Use
- Acronyms ROADMAP
- 25 Sep 2013 Results of the pre-specified ECG analysis (n=1513) presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 10 Mar 2011 Results published in the New England Journal of Medicine.
- 24 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD), 2010.